Triple-negative breast cancer: radiation, immunotherapy, and chemo before surgery
Part of Cancer, Skin clinical trials.
This trial tests a combination of targeted radiation, immunotherapy, and chemotherapy before surgery for triple-negative breast cancer. It aims to see if this approach improves treatment response in patients with a low PD-L1 score.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer that is newly diagnosed and has not spread to distant organs.
- Your tumor is at least 2 cm in size or has spread to nearby lymph nodes.
- You have a PD-L1 CPS score of less than 10 (a measure of a protein on your cancer cells).
- You are in good overall health (able to do daily activities) and have adequate blood counts and organ function.
- You have not had another cancer or autoimmune disease that could affect your safety.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for breast cancer that combines a short course of focused radiation (SBRT) with an injection of the immunotherapy drug pembrolizumab directly into the tumor, followed by standard chemotherapy before surgery. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.